Mehdi Shishehbor is a Cardiologist and an Interventional Cardiologist in Cleveland, Ohio. Shishehbor has been practicing medicine for over 24 years and is rated as an Elite expert by MediFind in the treatment of Peripheral Artery Disease. He is also highly rated in 19 other conditions, according to our data. His top areas of expertise are Peripheral Artery Disease, Atherosclerosis, Arterial Insufficiency, Angioplasty, and Atherectomy. He is licensed to treat patients in Ohio. Shishehbor is currently accepting new patients.
Jeffrey Berger is a Cardiologist in New York, New York. Berger has been practicing medicine for over 22 years and is rated as an Elite expert by MediFind in the treatment of Peripheral Artery Disease. He is also highly rated in 23 other conditions, according to our data. His top areas of expertise are Peripheral Artery Disease, Atherosclerosis, Carotid Artery Disease, Coronary Artery Bypass Graft (CABG), and Heart Bypass Surgery. He is licensed to treat patients in North Carolina. Berger is currently accepting new patients.
Manesh Patel is an Interventional Cardiologist and a Cardiologist in Durham, North Carolina. Patel has been practicing medicine for over 26 years and is rated as an Elite expert by MediFind in the treatment of Peripheral Artery Disease. He is also highly rated in 29 other conditions, according to our data. His top areas of expertise are Peripheral Artery Disease, Atherosclerosis, Coronary Heart Disease, Percutaneous Coronary Intervention (PCI), and Angioplasty. He is licensed to treat patients in North Carolina. Patel is currently accepting new patients.
Summary: This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes. Participants will either get semaglutide or placebo (dummy) medicine - which treatment participants get is decided by chance. Semaglutide is a medicine for type 2 diabetes that can be prescribed by doctors in some cou...
Summary: The purpose of this study is to demonstrate improvement in flow mediated dilation (FMD), a functional endpoint associated with the progression of atherosclerosis, when switching from cigarettes to the Tobacco Heating System (THS) in subjects with peripheral arterial disease (PAD) and/or coronary artery disease (CAD). The study is planned to be conducted in the US, Europe, and Asia.